Hematology-American Society of Hematology Education Program

Article	Citations
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	57
Clots in unusual places: lots of stress, limited data, critical decisions	54
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	49
Acute GVHD: think before you treat	34
Provoked vs minimally provoked vs unprovoked VTE: does it matter?	33
Thrombocytopenia in pregnancy	31
How do we optimally utilize factor concentrates in persons with hemophilia?	31
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	29
Recognizing, defining, and managing CAR-T hematologic toxicities	27
Optimal approach to T-cell ALL	25
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy	24
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	24
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	23
What factors guide treatment selection in mycosis fungoides and Sezary syndrome?	22
Diagnosis and therapeutic decision-making for the neutropenic patient	21
Mastocytosis demystified	21
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	21
Controversies in the management of early-stage Hodgkin lymphoma	21
Evidence-Based Minireview: Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia	20
The dos, don'ts, and nuances of thrombophilia testing	18
Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML	18
AL amyloidosis: untangling new therapies	17
Dual-targeted regimens for the frontline treatment of CLL	17
Relapsed ALL: CAR T vs transplant vs novel therapies	17
Bispecific antibody therapies	17

Lifelong TKI therapy: how to manage cardiovascular and other risks	17
Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?	16
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	16
What have we learned about the patient's experience of von Willebrand disease? A focus on women	16
Biology of follicular lymphoma: insights and windows of clinical opportunity	16
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	16
Modern management of Fanconi anemia	16
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies	16
Cytoreduction for ET and PV: who, what, when, and how?	16
Labor and delivery: DIC, HELLP, preeclampsia	16
Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? Hematology Am Soc Hematol Educ Program. 2021;2021:521-528.	15
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	15
Novel platelet products including cold-stored platelets	15
Management of Fanconi anemia beyond childhood	15
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	15
Your chemo is no good here: management of high-risk MCL	14
Novel conditioning and prophylaxis regimens for relapse prevention	14
Treatment of VTE in the thrombocytopenic cancer patient	14
Risk-stratification in frontline CLL therapy: standard of care	13
Mutations and MRD: clinical implications of clonal ontogeny	13
On the horizon: upcoming new agents for the management of ITP	13
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	13
New definitions for antiphospholipid syndrome: ready for clinical use?	13
Neurological manifestations of MGUS	13
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	13
The POD24 challenge: where do we go from here for early progressors?	13
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients	12
Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation	12
Gene therapy for hemophilia	12
Pegylated interferon: the who, why, and how	12
Anticoagulation at the end of life: whether, when, and how to treat	12
Dyskeratosis congenita and telomere biology disorders	11
Novel immunotherapies in the treatment of AML: is there hope?	11
Inpatient recognition and management of HLH	11
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	11
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	10
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	10
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	10
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	10
Diagnostic pitfalls and conundrums in type 1 von Willebrand disease	10
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	10
Has PD-1 blockade changed the standard of care for cHL?	10
Challenges in hospice and end-of-life care in the transfusion-dependent patient	9
Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations	9
Updates on strategies to integrate palliative care in hematologic malignancy	9
Givosiran: a targeted treatment for acute intermittent porphyria	9
In pursuit of a functional cure for follicular lymphoma	9
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	9
Targeted medical therapies for vascular anomalies	9
What is the ideal approach—doublet, triplet, or quadruplet(s)?	9

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy	9
Modified T cells as therapeutic agents	8
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	8
Have we reached a molecular era in myelodysplastic syndromes?	8
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	8
What makes a pediatric or young adult patient an appropriate transplant candidate?	8
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	8
Biology of post-transplant relapse: actionable features	8
Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy	8
Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy	7
Novel approaches to acute graft-versus-host disease prevention	7
Passive immune therapies: another tool against COVID-19	7
Clinical manifestations of telomere biology disorders in adults	7
Options at the time of relapse after anti-BCMA therapy	7
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma	7
Using disease-modifying therapies in sickle cell disease	7
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	7
Resistance mutations in CML and how we approach them	7
Amyloid consults do not have to be vexing	7
Pyruvate kinase activators for treatment of pyruvate kinase deficiency	7
Multiple myeloma: a paradigm for blending community and academic care	7
Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?	7
How to avoid early mortality in acute promyelocytic leukemia	7
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	7
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	7
T-cell lymphopenia in frequent volunteer platelet donors	7
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	7
Molecular prognostication in Ph-negative MPNs in 2022	7
Upfront therapy: the case for continuous treatment	7
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	7
Identifying and treating iron deficiency anemia in pregnancy	6
Williams KM. Noninfectious complications of hematopoietic cell transplantation. Hematology Am Soc Hematol Educ Program. 2021;2021:578-586.	6
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	6
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	6
Platelet components and bacterial contamination: hospital perspective 2022	6
Allogeneic transplantation for advanced acute leukemia	6
Evidence-based management of pregnant women with sickle cell disease in high-income countries	6
Cold AIHA and the best treatment strategies	6
Next-generation therapy for lower-risk MDS	6
Fitness and frailty in myeloma	6
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	6
Diagnosis and laboratory monitoring of acquired hemophilia A	6
Medical consult: aHUS, TTP? How to distinguish and what to do	6
Perioperative consultative hematology: can you clear my patient for a procedure?	6
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	6
Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia	6
Long-term health outcomes following curative therapies for sickle cell disease	6
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	6
The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure	6
Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?	6
Ph− ALL: immunotherapy in upfront treatment	6
Heparin-induced thrombocytopenia and cardiovascular surgery	6
Divergent paths: management of early relapsed follicular lymphoma	5
Managing side effects: guidance for use of immunotherapies in multiple myeloma	5
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too	5
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT	5
Inflamed—HLH, MAS, or something else?	5
Prevention, diagnosis, and management of PE and DVT in pregnant women	5
Whom should we treat with novel agents? Specific indications for specific and challenging populations	5
The first relapse in multiple myeloma: how to pick the next best thing	5
Selecting initial therapy in CLL	5
Optimal approach to T-cell ALL	5
How to assess hemostasis in patients with severe liver disease	5
When to consider inherited marrow failure syndromes in adults	5
Evidence-Based Minireview: When should autologous transplant or cellular therapy be considered for follicular lymphoma?	5
Evidence-based obstetric management of women with sickle cell disease in low-income countries	5
Mutational screening to improve the transplantation decision-making process in MDS	5
Management of aggressive lymphoma after CAR T-cell therapy failure	5
Approaches to optimize outcomes in transplant recipients	5
Pyruvate kinase activators: targeting red cell metabolism in thalassemia	5
Frontline treatment in CLL: the case for time-limited treatment	4
How to recognize and manage COVID-19-associated coagulopathy	4
Gene therapy for sickle cell disease	4
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?	4
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL	4
New approaches to tackle cytopenic myelofibrosis	4
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	4
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	4
Achieving MRD negativity in AML: how important is this and how do we get there?	4
Clonal evolution in inherited marrow failure syndromes predicts disease progression	4

Novel therapies upon failure of HMA plus venetoclax	4
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	4
Diagnosis and clinical management of red cell membrane disorders	4
Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?	4
Current use of CAR T cells to treat multiple myeloma	4
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	4
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	4
Advances in the management of α-thalassemia major: reasons to be optimistic	4
Optimizing outcomes in secondary AML	4
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas	3
Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?	3
COVID-19 and thrombosis: searching for evidence	3
BV and beyond: how to incorporate novel agents into PTCL management	3
Incorporating gonadal health counseling into pediatric care of sickle cell patients	3
IgG4-related disease for the hematologist	3
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	3
The role of stem cell transplant (auto and allo) in PTCL and CTCL	3
Troubleshooting heparin resistance	3
The intersection of sickle cell disease, stigma, and pain in Africa	3
Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond	3
Practical guide for disease-modifying medication management of children and adolescents with sickle cell disease	3
Treatment of Richter's syndrome	3
Transplant in myeloma: who, when, and why?	3
Renal manifestations of MGUS	3
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	3
When to use stem cell transplantation for classical Hodgkin lymphoma	3
Should we use bisphosphonates to treat bone complications in sickle cell disease?	3
Newborn screening initiatives for sickle cell disease in Africa	3
Sequencing bispecific antibodies and CAR T cells for FL	3
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	3
Supportive care in myeloma—when treating the clone alone is not enough	3
MGCS: where do we stand today?	3
Does MRD have a role in the management of iNHL?	3
Newly diagnosed multiple myeloma: making sense of the menu	2
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	2
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	2
MRD-directed therapy in CLL: ready for prime time?	2
Blast and accelerated phase CML: room for improvement	2
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	2
Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?	2
Diamond-Blackfan anemia	2
How to manage hemostasis in patients with liver disease during interventions	2
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	2
Treatment of older adult or frail patients with multiple myeloma	2
Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy	2
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	2
Approach to the patient with suspected hypereosinophilic syndrome	2
Transplant for TP53-mutated MDS and AML: because we can or because we should?	2
The burden of myeloma: novel approaches to disease assessment	2
Risk factors and screening for neurocognitive impacts of therapy	2
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	2
The 5 most frequently asked questions about factor Xa inhibitors	2
How to diagnose and manage antiphospholipid syndrome	2
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	2
What else do I need to worry about when treating graft-versus-host disease?	2
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	2
New investigational combinations for higher-risk MDS	2